🇺🇸 FDA
Patent

US 8242085

Tetrahydrofuro [3,4-D] dioxolane compounds for use in the treatment of viral infections and cancer

granted A61PA61P31/12A61P31/14

Quick answer

US patent 8242085 (Tetrahydrofuro [3,4-D] dioxolane compounds for use in the treatment of viral infections and cancer) held by BioCryst Pharmaceuticals, Inc. expires Mon Aug 09 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BioCryst Pharmaceuticals, Inc.
Grant date
Tue Aug 14 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 09 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
46
CPC classes
A61P, A61P31/12, A61P31/14, A61P31/16, A61P31/18